Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of “Hold” by Brokerages

Grifols, S.A. (NASDAQ:GRFS) has been given a consensus recommendation of “Hold” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Zacks Research lowered Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. Finally, Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc increased its stake in Grifols by 39.5% during the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,584 shares during the period. Peterson Wealth Services increased its position in shares of Grifols by 385.8% during the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 5,787 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 4,604 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Grifols by 109.8% in the third quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 4,518 shares during the period. Finally, R Squared Ltd acquired a new stake in Grifols in the 2nd quarter valued at about $95,000.

Grifols Stock Performance

NASDAQ:GRFS opened at $9.37 on Monday. The company’s 50-day moving average is $8.91 and its two-hundred day moving average is $9.51. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.48 and a quick ratio of 0.93. The firm has a market capitalization of $6.44 billion, a price-to-earnings ratio of 49.32, a PEG ratio of 0.33 and a beta of 0.67. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.